Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25439275 | 1.00 | MEN1 (0.56) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL30584822 | 0.92 | MEN1 (0.60) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL31667442 | 0.92 | MEN1 (0.60) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL31667729 | 0.92 | MEN1 (0.60) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL31667455 | 0.92 | MEN1 (0.60) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL31546454 | 0.92 | MEN1 (0.61) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL31546409 | 0.92 | MEN1 (0.61) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL30584978 | 0.92 | MEN1 (0.54) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL30584852 | 0.92 | MEN1 (0.54) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL30584709 | 0.92 | MEN1 (0.54) | MEN1KMT2ALMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023177700-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2023-09-21 | — | — | WO | disclosed |